

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
		Day	Month	Year	Unk	Male	Unk	Day	Month	Year	
			PRIVACY						Unk		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
The patient underwent a biopsy on the neck 4 months ago, does not provide exact dates. [Biopsy]	ACALABRUTINIB	No	No	Not Related	Not Related
Patient presents lymph nodes in the neck, for the past 22 days. Does not provide exact dates./ Patient has been presenting lymph nodes in the chest for 22 days. Does not provide exact dates./ Patient presents lymph nodes on the back, for the past 22 d [Lymphadenopathy]	ACALABRUTINIB	No	No	Not Related	Not Related

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) ACALABRUTINIB (ACALABRUTINIB) Film-coated tablet		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 100 milligram, bid	16. ROUTE(S) OF ADMINISTRATION #1) Oral use	
17. INDICATION(S) FOR USE #1) Chronic Lymphocytic Leukemia (Chronic lymphocytic leukaemia)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Ongoing	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates Unknown to Ongoing Unknown	Type of History / Notes Indication Historical Condition	Description Chronic lymphocytic leukemia (Chronic lymphocytic leukemia) Tumor (Neoplasm)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorgiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000		26. REMARKS World Wide #: CR-ASTRAZENECA-202507CAM001463CR Study ID: PSP-23269 Case References: CR-AstraZeneca-CH-00903357A
	24b. MFR CONTROL NO. 202507CAM001463CR	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 02-JUL-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 04-JUL-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

04-Jul-2025 15:34

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
The patient showed a little depression. [Depression]	ACALABRUTINIB	No	No	Not Related	Not Related

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a male patient born in 1952.

The patient's past and current medical history included tumor (dates not reported).

No concomitant products were reported.

The patient started treatment with Acalabrutinib (acalabrutinib) 100 milligram bid, Oral use, on an unknown date for chronic lymphocytic leukemia.

On an unknown date, the patient experienced the patient underwent a biopsy on the neck 4 months ago, does not provide exact dates. (preferred term: Biopsy), the patient showed a little depression. (preferred term: Depression) and patient presents lymph nodes in the neck, for the past 22 days. does not provide exact dates./ patient has been presenting lymph nodes in the chest for 22 days. does not provide exact dates./patient presents lymph nodes on the back, for the past 22 d (preferred term: Lymphadenopathy).

The dose of Acalabrutinib (acalabrutinib) was not changed.

The patient recovered from the event(s) the patient showed a little depression. and the patient underwent a biopsy on the neck 4 months ago, does not provide exact dates. on an unspecified date. At the time of reporting, the event patient presents lymph nodes in the neck, for the past 22 days. does not provide exact dates./ patient has been presenting lymph nodes in the chest for 22 days. does not provide exact dates./patient presents lymph nodes on the back, for the past 22 d was ongoing.

The events were considered non-serious.

The reporter did not consider that there was a reasonable possibility of a causal relationship between Acalabrutinib and the following event(s): patient presents lymph nodes in the neck, for the past 22 days. does not provide exact dates./ patient has been presenting lymph nodes in the chest for 22 days. does not provide exact dates./patient presents lymph nodes on the back, for the past 22 d, the patient showed a little depression. and the patient underwent a biopsy on the neck 4 months ago, does not provide exact dates.. The company physician did not consider that there was a reasonable possibility of a causal relationship between Acalabrutinib and the following event(s): patient presents lymph nodes in the neck, for the past 22 days. does not provide exact dates./ patient has been presenting lymph nodes in the chest for 22 days. does not provide exact dates./patient presents lymph nodes on the back, for the past 22 d, the patient showed a little depression. and the patient underwent a biopsy on the neck 4 months ago, does not provide exact dates..

Laboratory values are available.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Computerised tomogram Unknown		